TETRAVECTA Trademark
TETRAVECTA is a USPTO trademark filed by Oxford BioMedica Plc. Status: Pending.
Trademark Facts
| Mark | TETRAVECTA |
|---|---|
| Serial Number | 98432248 |
| Status | Pending |
| Filing Date | 2024-03-04 |
| Mark Type | Word |
| Nice Classes | 040 (Material Treatment), 042 (Software & IT) |
| Owner | Oxford BioMedica Plc |
| Attorney of Record | Rebeccah Gan |
| Prosecution Events | 26 |
| Latest Event | CNSI on 2026-04-25 |
Goods & Services
Class 040: Custom manufacture of products relating to biotechnology, namely, custom manufacture of biopharmaceuticals for use in cell and gene therapies; custom manufacture of gene and cell-based therapy products, namely, genetically engineered cells and tissues for cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of biopharmaceuticals used in cell and gene therapies, and biopharmaceutical preparations; biotechnology contract manufacturing services, namely, contract manufacturing in the field of pharmaceuticals and biopharmaceuticals for cell and gene therapy using biological organisms in the manufacturing process; contract manufacturing services of gene and cell-based therapy products, namely, biopharmaceuticals for cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of biopharmaceuticals for cell and gene therapies and biopharmaceutical products, namely, biopharmaceuticals for cell and gene therapies; contract manufacturing services of technology for biopharmaceutical products and gene and cell-based products, namely, custom manufacture of biopharmaceuticals for cell and gene therapies; contract manufacturing services of technology for viral vectors, retroviral vectors, lentiviral vectors, adeno-associated viral vectors, adenoviral vectors, and non-vector preparations, namely, custom manufacture of pharmaceuticals and biopharmaceuticals for cell and gene therapies; Class 042: Research and laboratory analytic and diagnostic services, namely, scientific research, biochemical research, research laboratory analysis services in the field of gene therapy and biochemistry; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; product, viral vector product and analytic assay product development for others; laboratory services, namely, scientific laboratory services and biological research laboratory services; research and development services, namely, gene therapy research; genetic engineering laboratories, namely, scientific research in the field of genetic engineering provided in genetic engineering laboratories and biochemistry laboratories providing research and development in the field of biochemistry; scientific and technological services and research, namely, scientific research, analysis, testing in the fields of gene therapy and biochemistry; industrial analysis services, namely, providing testing analysis services with respect to gene-therapy based product manufacturing for industrial purposes; provision of information relating to scientific research; provision of scientific information in the fields of gene therapy and biochemistry; product research and scientific analysis of cell and gene therapies relating to drug discovery and product development for others; scientific advisory services relating to biochemistry; scientific consultancy services relating to biochemistry; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals